相关实验视频

Updated: Jun 23, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

来自假定大麻种子水解体的二乙酶-IV抑制的计算查作为潜在的抗糖尿病剂

Arisa Thongtak¹, Kulpariya Yutisayanuwat¹, Nathaphat Harnkit²

¹Mahidol Wittayanusorn School, 364 Salaya, Phuttamonthon District, Nakhon Pathom 73170, Thailand.

International journal of molecular sciences

|June 19, 2024

概括

研究人员探索了大麻种子作为2型糖尿病的潜在抗高血糖剂. 两个,FNVDTE和EAQPST,显示出作为二二酶-IV (DPPIV) 抑制剂的潜力,有可能成为替代糖尿病治疗方法.

科学领域:

生物化学和分子生物学
营养科学营养科学
计算生物学计算生物学

背景情况:

2 型糖尿病与减少的 GLP-1 激素水平有关,因为 dipeptidyl peptidase-IV (DPPIV) 会降解激素.
目前的DPPIV抑制剂,如维尔达格利普丁,西塔格利普丁和林纳格利普丁,具有潜在的副作用,需要替代治疗.
食物衍生的是一种新型治疗剂的潜在来源.

研究的目的:

为了识别和评估来自大麻种子的食品衍生,以检测其皮酶-IV (DPPIV) 抑制活性.
使用in silico预测工具评估潜在的DPPIV抑制的安全性.
探索大麻种子衍生的治疗潜力,作为抗高血糖剂.

主要方法:

生物信息学管道用于各种蛋白质酶的种子蛋白 (白蛋白,埃德斯,维西林) 的化消化.
使用IDPPIV-SCM对DPPIV抑制的查,并通过TOXINpred,AllerCatPro和HemoPred评估安全性.
分子对接,3D可视化和分子动力学模拟以分析蛋白相互作用.

主要成果:

鉴定了一种大麻种子蛋白质的假定水解体.
类FNVDTE (来自edestin) 和EAQPST (来自vicilin) 被预测为强大的DPPIV抑制剂.
在体安全性评估表明,这些候选的特征是有利的.

结论:

大麻种子,特别是FNVDTE和EAQPST,显示出作为DPPIV抑制剂的显著潜力.
这些发现表明,开发新型,来自食物的抗高血糖药物治疗2型糖尿病是一个有希望的途径.
对这些的进一步研究可能会导致对现有的DPPIV抑制药物的更安全替代品.

关键词:

大麻sativa是一种大麻.生物信息学是一种生物信息学.糖尿病糖尿病患者糖尿病患者双基酸酶-IV 是一种二基酸酶.

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...